Hippokration General Hospital of Thessaloniki
Thessaloniki, Central Makedonia, Greece
Location status: Recruiting
Location contact
Athanasios Christoforidis
PRINCIPAL_INVESTIGATOR
Athina Stamati
CONTACT
NCT Number: NCT07483879
Diabetic ketoacidosis (DKA) is a severe metabolic complication in children with newly diagnosed type 1 diabetes mellitus (T1DM) and may be associated with early injury of vital organs such as the kidneys and the heart. Early detection of organ dysfunction is important for identifying children at increased risk for complications.
This observational cross-sectional study aims to evaluate biomarkers of acute organ injury and associated clinical and echocardiographic parameters in children with newly diagnosed T1DM presenting with DKA, compared with children with newly diagnosed T1DM without DKA and healthy controls. Biomarkers including KIM-1, NGAL, high-sensitivity troponin, NT-proBNP, interleukin-6, and C-reactive protein will be measured during hospital admission and within the first 24-48 hours of hospitalization.
Interested in participating?
Request Info2 year–16 year
All sexes
Observational
Thessaloniki, Central Makedonia, Greece
Location status: Recruiting
Athanasios Christoforidis
PRINCIPAL_INVESTIGATOR
Athina Stamati
CONTACT
Diabetic ketoacidosis (DKA) is a common and potentially life-threatening metabolic complication in children with newly diagnosed type 1 diabetes mellitus (T1DM). In addition to the acute metabolic disturbances, DKA may lead to early or subclinical injury of vital organs, particularly the kidneys and the cardiovascular system, due to dehydration, hypovolemia, metabolic acidosis, electrolyte disturbances, and inflammatory activation.
Recent studies suggest that novel biomarkers may allow early detection of organ dysfunction before conventional clinical indicators become abnormal. Biomarkers such as kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), cystatin C, high-sensitivity troponin (hs-troponin), and N-terminal pro-B-type natriuretic peptide (NT-proBNP) have been proposed as sensitive indicators of kidney and myocardial injury. Inflammatory markers such as interleukin-6 (IL-6) and C-reactive protein (CRP) may also reflect systemic inflammatory activation associated with metabolic decompensation.
The aim of this observational cross-sectional study is to investigate and compare biomarkers of acute organ injury and related clinical and echocardiographic parameters in children with newly diagnosed T1DM presenting with DKA, compared with children with newly diagnosed T1DM without DKA and healthy controls.
Participants will be categorized into three groups: (1) children with newly diagnosed T1DM presenting with DKA, (2) children with newly diagnosed T1DM without DKA, and (3) healthy children serving as controls. Blood samples will be collected at hospital admission for measurement of biomarkers including KIM-1, NGAL, hs-troponin, NT-proBNP, IL-6, and CRP, as well as standard laboratory parameters such as serum creatinine, cystatin C, albuminuria, pH, bicarbonate levels, and HbA1c.
All participants with T1DM will undergo cardiological evaluation including clinical examination, electrocardiogram, and transthoracic echocardiography with conventional measurements as well as advanced techniques such as tissue Doppler imaging and speckle-tracking echocardiography. Data collection will be performed at admission and within the first 24-48 hours of hospitalization.
The primary objective of the study is to compare biomarker levels and clinical parameters among the three study groups in order to identify early evidence of acute or subclinical organ dysfunction associated with diabetic ketoacidosis in children with newly diagnosed T1DM.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
For control group:
Exclusion criteria
Blood and urine samples and echocardiographic evaluation performed as part of the clinical assessment of children with newly diagnosed type 1 diabetes.
Time frame: Within 48 hours of hospitalization
Measurement of neutrophil gelatinase-associated lipocalin (NGAL, ng/mL) as a biomarker of early renal injury in children with newly diagnosed type 1 diabetes.
Time frame: Within 48 hours of hospitalization
Measurement of kidney injury molecule-1 (KIM-1, ng/mL) as a biomarker of renal injury in children with newly diagnosed type 1 diabetes.
Time frame: Within 48 hours of hospitalization
Measurement of high-sensitivity troponin (hs-troponin, ng/L) as a biomarker of myocardial injury in children with newly diagnosed type 1 diabetes.
Time frame: Within 48 hours of hospitalization
Measurement of N-terminal pro-B-type natriuretic peptide (NT-proBNP, pg/mL) as a biomarker of cardiac stress in children with newly diagnosed type 1 diabetes.
Time frame: Within 48 hours of hospitalization
Measurement of interleukin-6 (IL-6, pg/mL) as a biomarker of systemic inflammation in children with newly diagnosed type 1 diabetes.
Time frame: Within 48 hours of hospitalization
Measurement of C-reactive protein (CRP, mg/L) as a biomarker of systemic inflammation in children with newly diagnosed type 1 diabetes.
Time frame: Within 48 hours of hospitalization
Measurement of serum creatinine (mg/dL) in children with newly diagnosed type 1 diabetes.
Time frame: Within 48 hours of hospitalization
Measurement of and cystatin C (mg/L) in children with newly diagnosed type 1 diabetes.
Time frame: Within 48 hours of hospitalization
Assessment of left ventricular systolic function using left ventricular ejection fraction measured by transthoracic echocardiography.
Time frame: Within 48 hours of hospitalization
Evaluation of left ventricular systolic function using fractional shortening measured by transthoracic echocardiography.
Time frame: Within 48 hours of hospitalization
Assessment of left ventricular diastolic function using the ratio of transmitral early filling velocity (E) to tissue Doppler early diastolic velocity (e').
Time frame: Within 48 hours of hospitalization
Assessment of subclinical left ventricular systolic function using global longitudinal strain derived from speckle-tracking echocardiography.
Time frame: Within 48 hours of hospitalization
Measurement of glutamic acid decarboxylase antibodies (GAD65) in children with newly diagnosed type 1 diabetes.
Time frame: Within 48 hours of hospitalization
Measurement of insulin autoantibodies (IAA) in children with newly diagnosed type 1 diabetes.
Time frame: Within 48 hours of hospitalization
Measurement of islet antigen-2 antibodies (IA-2) in children with newly diagnosed type 1 diabetes.
Time frame: Within 48 hours of hospitalization
Measurement of zinc transporter 8 antibodies (ZnT8) in children with newly diagnosed type 1 diabetes.
Time frame: Baseline
Classification of diabetic ketoacidosis severity at hospital admission based on venous blood pH and serum bicarbonate levels according to international pediatric guidelines. Diabetic ketoacidosis will be categorized as mild (pH <7.30, bicarbonate <15 mmol/L), moderate (pH <7.20, bicarbonate <10 mmol/L), or severe (pH <7.10, bicarbonate <5 mmol/L).
Contact information is provided by the study sponsor or research team.
Aristotle University Of Thessaloniki
Other
Evaluation of Biomarkers and Clinical Parameters of Acute Organ Injury in Children With Newly Diagnosed Type 1 Diabetes: The Effect of Diabetic Ketoacidosis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03107208
Acid-Base Imbalance, Acidosis
Aurora, Colorado, United States
View Trial DetailsNCT04656236
Acid-Base Imbalance, Acidosis
Aarhus, Denmark
View Trial DetailsNCT03128229
Acid-Base Imbalance, Acidosis
Aurora, Colorado, United States
View Trial DetailsNCT07325201
Acid-Base Imbalance, Acidosis
Minneapolis, Minnesota, United States
View Trial Details